UA124793C2 - Заміщені похідні ксантину - Google Patents

Заміщені похідні ксантину Download PDF

Info

Publication number
UA124793C2
UA124793C2 UAA202000735A UAA202000735A UA124793C2 UA 124793 C2 UA124793 C2 UA 124793C2 UA A202000735 A UAA202000735 A UA A202000735A UA A202000735 A UAA202000735 A UA A202000735A UA 124793 C2 UA124793 C2 UA 124793C2
Authority
UA
Ukraine
Prior art keywords
intermediate compound
disorder
disorders
mmol
disease
Prior art date
Application number
UAA202000735A
Other languages
English (en)
Ukrainian (uk)
Inventor
Кай Ґерлах
Кай Герлах
Кристіан Айкмайер
Кристиан Айкмайер
Ахім Зауер
Ахим Зауер
Штефан Юст
Бертран Л. Шенар
Original Assignee
Берінґер Інґельгайм Інтернаціональ Ґмбг
Берингер Ингельгайм Интернациональ Гмбг
Гайдра Байосайенсиз, Елелсі
Гайдра Байосайенсиз, Элэлси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Берінґер Інґельгайм Інтернаціональ Ґмбг, Берингер Ингельгайм Интернациональ Гмбг, Гайдра Байосайенсиз, Елелсі, Гайдра Байосайенсиз, Элэлси filed Critical Берінґер Інґельгайм Інтернаціональ Ґмбг
Publication of UA124793C2 publication Critical patent/UA124793C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UAA202000735A 2017-07-11 2018-07-06 Заміщені похідні ксантину UA124793C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17180721 2017-07-11
PCT/EP2018/068366 WO2019011802A1 (en) 2017-07-11 2018-07-06 NEW SUBSTITUTED XANTHINE DERIVATIVES

Publications (1)

Publication Number Publication Date
UA124793C2 true UA124793C2 (uk) 2021-11-17

Family

ID=59325162

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA202000735A UA124793C2 (uk) 2017-07-11 2018-07-06 Заміщені похідні ксантину

Country Status (32)

Country Link
US (1) US10329292B2 (cg-RX-API-DMAC7.html)
EP (1) EP3652176B1 (cg-RX-API-DMAC7.html)
JP (1) JP7114702B2 (cg-RX-API-DMAC7.html)
KR (1) KR102714554B1 (cg-RX-API-DMAC7.html)
CN (1) CN110997675B (cg-RX-API-DMAC7.html)
AR (1) AR112448A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018299824B2 (cg-RX-API-DMAC7.html)
CA (1) CA3066922A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020000056A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019015102A2 (cg-RX-API-DMAC7.html)
CY (1) CY1125014T1 (cg-RX-API-DMAC7.html)
DK (1) DK3652176T3 (cg-RX-API-DMAC7.html)
EA (1) EA039526B1 (cg-RX-API-DMAC7.html)
ES (1) ES2903268T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220029T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057600T2 (cg-RX-API-DMAC7.html)
IL (1) IL271799B (cg-RX-API-DMAC7.html)
LT (1) LT3652176T (cg-RX-API-DMAC7.html)
MX (1) MX394089B (cg-RX-API-DMAC7.html)
MY (1) MY200797A (cg-RX-API-DMAC7.html)
PE (1) PE20200861A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020500079A1 (cg-RX-API-DMAC7.html)
PL (1) PL3652176T3 (cg-RX-API-DMAC7.html)
PT (1) PT3652176T (cg-RX-API-DMAC7.html)
RS (1) RS62826B1 (cg-RX-API-DMAC7.html)
SA (1) SA519410851B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201912168TA (cg-RX-API-DMAC7.html)
SI (1) SI3652176T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200013T1 (cg-RX-API-DMAC7.html)
TW (1) TWI801398B (cg-RX-API-DMAC7.html)
UA (1) UA124793C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019011802A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019231208B2 (en) * 2018-03-05 2025-01-23 Gfb (Abc), Llc Imidazodiazepinediones and methods of use thereof
US12291532B2 (en) 2018-12-12 2025-05-06 Boehringer Ingelheim International Gmbh Substituted xanthines as modulators of TRPC5 activity
IL283768B2 (en) * 2018-12-12 2024-05-01 Boehringer Ingelheim Int Xanthine histories are transmuted
AU2020357178A1 (en) * 2019-10-04 2022-05-12 Gfb (Abc), Llc Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease
CN118373832B (zh) * 2023-01-20 2025-01-28 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用
KR20250141831A (ko) 2023-02-08 2025-09-29 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 잔틴계 화합물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1953162T1 (sl) * 2001-02-24 2012-09-28 Boehringer Ingelheim Pharma Ksantinski derivati, njihova priprava in njihova uporaba kot zdravila
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
ATE496894T1 (de) * 2006-07-14 2011-02-15 Pfizer Prod Inc Tartratsalz von (7s)-7-ä(5-fluor-2-
MX370372B (es) * 2013-03-15 2019-12-11 Hydra Biosciences Inc Xantinas sustituidas y metodos de uso de las mismas.
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位a1離子通道
EP3180340B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーHydra Biosciences, LLC ピロロ[3,2−d]ピリミジン−2,4(3H,5H)−ジオン誘導体
EP3194367B1 (en) 2014-09-17 2021-08-18 Boehringer Ingelheim International GmbH Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes

Also Published As

Publication number Publication date
EP3652176A1 (en) 2020-05-20
PT3652176T (pt) 2022-01-13
US20190016722A1 (en) 2019-01-17
EA039526B1 (ru) 2022-02-07
PE20200861A1 (es) 2020-08-25
TWI801398B (zh) 2023-05-11
KR20200030048A (ko) 2020-03-19
CO2019015102A2 (es) 2020-05-15
BR112019025611A2 (pt) 2020-06-16
EP3652176B1 (en) 2021-12-15
HUE057600T2 (hu) 2022-05-28
SI3652176T1 (sl) 2022-04-29
US10329292B2 (en) 2019-06-25
HRP20220029T1 (hr) 2022-04-15
CN110997675A (zh) 2020-04-10
AR112448A1 (es) 2019-10-30
JP7114702B2 (ja) 2022-08-08
RS62826B1 (sr) 2022-02-28
MY200797A (en) 2024-01-16
SA519410851B1 (ar) 2023-02-26
PL3652176T3 (pl) 2022-04-04
WO2019011802A1 (en) 2019-01-17
DK3652176T3 (da) 2022-01-17
PH12020500079A1 (en) 2020-10-05
SMT202200013T1 (it) 2022-03-21
MX2020000402A (es) 2020-08-17
CL2020000056A1 (es) 2020-06-12
EA202090270A1 (ru) 2020-04-24
LT3652176T (lt) 2022-02-25
CA3066922A1 (en) 2019-01-17
KR102714554B1 (ko) 2024-10-10
CY1125014T1 (el) 2023-03-24
ES2903268T3 (es) 2022-03-31
AU2018299824B2 (en) 2022-06-16
CN110997675B (zh) 2022-06-07
MX394089B (es) 2025-03-24
IL271799A (en) 2020-02-27
JP2020526591A (ja) 2020-08-31
AU2018299824A1 (en) 2019-12-19
NZ759728A (en) 2024-11-29
IL271799B (en) 2022-08-01
SG11201912168TA (en) 2020-01-30
TW201908318A (zh) 2019-03-01

Similar Documents

Publication Publication Date Title
KR102714554B1 (ko) 신규한 치환된 크산틴 유도체
UA123689C2 (uk) Імідазопіролопіридинові сполуки як інгібітори кіназ родини jак
JP2021518388A (ja) オキサジアゾール一過性受容器電位チャネル阻害剤
AU2010330048A1 (en) Imidazolidinedione derivatives
AU2013328586B2 (en) N-(2-(cyclic amine)ethyl)benzamide derivatives as P2x7 inhibitors
JP2025094157A (ja) Creb結合タンパク質(cbp)の阻害
US20200289508A1 (en) Novel pyrimidinyl-diazospiro compounds
EP3894409B1 (en) Substituted xanthine derivatives
JP7502299B2 (ja) 置換キサンチン誘導体
EP4604945A2 (en) Novel kv3 channel modulators
HK40025200A (en) Substituted xanthine derivatives
HK40025200B (en) Substituted xanthine derivatives
CA3119229C (en) Substituted xanthine derivatives
BR112019025611B1 (pt) Compostos derivados de xantina substituídos e sais dos mesmos
EA043969B1 (ru) Замещенные ксантиновые производные